Rachael is a writer and environmental consultant who advises nonprofits and foundations on climate change. With an expertise in tropical forests, Rachael has conducted fieldwork in the Brazilian and Ecuadorian Amazon, Borneo, Uganda and elsewhere. After almost a decade in climate policy, Rachael has turned her attention to the spiritual implications of our current ecological crises. Rachael stumbled into psychedelics as a participant in a psilocybin clinical trial for major depression. Her writing excavates the potential risks, rewards, and societal implications of medicalizing and commercializing mysticism. Her work interrogates the intersection of the mystical and the moral, and envisions the role of non-ordinary states of consciousness in current and future forms of religion. Rachael explores these themes as a Junior Fellow at Harvard University's Center for the Study of World Religions.
March 11, 2020
As technology and psychedelics turn to mental health, we’ll likely see a future where we are treated based on our digital biomarkers, and sold mental health services based on the personal data we surrender.
March 16, 2020
A long-fought battle for access to peyote, and a dwindling population in the United States has led Native American Church members and peyote conservationists to request that peyote be left out of decriminalization efforts.
March 25, 2020
“The Corona Virus is a necessary purge of what is no longer in resonance,” Trinity de Guzman wrote in a recent email to his followers.
April 4, 2020
The coronavirus has made it clear that psychedelic medicalization will not revolutionize mental healthcare without systemic socioeconomic change.
April 4, 2020
In response to the coronavirus pandemic, Christian Angermayer—the world's largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences—dismisses medical experts in his desperation to reboot the economy.
April 4, 2020
As the coronavirus pandemic rages on, Christian Angermayer, the world’s largest psychedelic pharmaceutical investor and founder of ATAI Life Sciences, calls to sacrifice public health for the sake of “the economy.”
April 8, 2020
Almost all clinical psychedelic drug research is being affected in some way or another by COVID-19. But, response measures vary from one organization to the next.
April 15, 2020
'Debbie and Doug Drop Acid in the Desert' director, Scott Brown, talks mind-altering drugs, creating psychedelic visual effects, and dealing with depression.
April 24, 2020
Contributors to the Daily Psychedelic Video platform gather on Zoom to bless the opening of the Psychedelic Video Museum: a collection of ten years’ worth of their shared visions.
April 25, 2020
Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”